Monopar Therapeutics MNPR Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Monopar Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's return on assets?
- Monopar Therapeutics (MNPR) reported return on assets of -15.5% in Q1 2026.
- How has Monopar Therapeutics's return on assets changed year-over-year?
- Monopar Therapeutics's return on assets increased by 70.0% year-over-year, from -51.8% to -15.5%.
- What is the long-term trend for Monopar Therapeutics's return on assets?
- Over 5 years (2020 to 2025), Monopar Therapeutics's return on assets has grown at a -20.0% compound annual growth rate (CAGR), from -41.7% to -13.6%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.